Form 8-K - Current report:
SEC Accession No. 0001193125-24-146454
Filing Date
2024-05-24
Accepted
2024-05-24 06:05:54
Documents
13
Period of Report
2024-05-23
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d818218d8k.htm   iXBRL 8-K 23714
  Complete submission text file 0001193125-24-146454.txt   149525

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fnch-20240523.xsd EX-101.SCH 2868
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fnch-20240523_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fnch-20240523_pre.xml EX-101.PRE 11719
16 EXTRACTED XBRL INSTANCE DOCUMENT d818218d8k_htm.xml XML 3768
Mailing Address 75 STATE STREET SUITE 100 BOSTON MA 02109
Business Address 75 STATE STREET SUITE 100 BOSTON MA 02109 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

EIN.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40227 | Film No.: 24980748
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)